Listar por autor "Oeconomou, A."
Mostrando ítems 1-8 de 8
-
Botulinum neurotoxin A for benign prostatic hyperplasia
Oeconomou, A.; Madersbacher, H. (2010)Purpose of review The injection of botulinum neurotoxin A (BoNT-A) into the prostate represents an alternative, minimal invasive treatment for lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH), ... -
THE BURDEN OF INCONTINENCE IN ASSOCIATION WITH LUTS AND SEXUAL FUNCTION: A QUESTIONNAIRE-BASED SURVEY ON TREATMENT SEEKING AND EXPECTATIONS
Oeconomou, A.; Nakopoulou, E.; Kalaitzi, M.; Tzortzis, V.; Ioannides, E. I.; Melekos, M.; Hatzichristou, D.; Apostolidis, A. (2011) -
Colonization by a linezolid-resistant Enterococcus faecalis caused a urinary tract infection
Mitsogiannis, I. C.; Oeconomou, A.; Karanika, M.; Petinaki, E.; Melekos, M. D. (2007) -
The combination of lanreotide 90 mg plus dexamethasone in the treatment of hormonerefractory prostate cancer (HRPCA)
Mitsogiannis, I.; Oeconomou, A.; Gravas, S.; Mitrakas, L.; Tzortzis, V.; Moutzouris, G.; Melekos, M. (2007) -
Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature
Oeconomou, A.; Madersbacher, H.; Kiss, G.; Berger, T. J.; Melekos, M.; Rehder, P. (2008)Context: The intraprostatic injection of botulinum neurotoxin type A (BoNT-A) is a minimally invasive but still-experimental treatment of lower urinary tract symptoms (LUTS) due to benign prostatic enlargment (BPE) based ... -
Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature Editorial Comment
Oeconomou, A.; Madersbacher, H.; Kiss, G.; Berger, T. J.; Melekos, M.; Rehder, P. (2009) -
Lack of association between the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and the risk of benign prostatic hyperplasia in Caucasian men
Karatzas, A.; Tzortzis, V.; Giannatou, E.; Gravas, S.; Zachos, I.; Oeconomou, A.; Melekos, M.; Tsezou, A. (2013)Glucuronidation, mediated by the UDP-glucuronosyltransferase 1A1 (UGT1A1) enzyme, is an important metabolic process during which steroids are converted to more easily excreted compounds in steroid target tissues, such as ... -
Reply to Giuseppe Brisinda, Serafino Vanella and Giorgio Maria's Letter to the Editor re: Athanassios Oeconomou, Helmut Madersbacher, Gustav Kiss, Thomas J. Berger, Michael Melekos and Peter Rehder. Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature. Eur Urol 2008;54:765-77
Oeconomou, A.; Melekos, M.; Madersbacher, H. (2009)